Scrip Asia Pacific

Asia Policy And Regulatory Bulletin

Ian Haydock — Fri, 25 Sep 2015 18:05:01 +0000

Below are highlights of policy- and regulation-oriented developments in Asia over the past couple of weeks, reported by our sister publication PharmAsia News , whose multilingual team of regional

Industry News Roundup

Mon, 27 Oct 2014 04:02:01 +0000

Mead Johnson sales up despite slump in China Investment analysts are squeamish about Mead Johnson Nutrition Co. ’s future despite the formula and nutritional beverage maker’s strong topline growth

In Brief: Novartis, Abbott Earnings; Using mL Cuts Mis-Dosing; Labels Need Proprietary Blend, Capsule Ingredients

Mon, 21 Jul 2014 04:01:42 +0000

Novartis consumer up 5% Novartis AG ’s consumer business gathers steam in advance of moving into a joint venture with GlaxoSmithKline PLC as net sales in its fiscal 2014 second quarter grow 5%

Sun Pharma’s $4B Ranbaxy Buy Brings Consumer Products Business With New Growth Focus

Jessica Merrill|Vikas Dandekar — Mon, 14 Apr 2014 04:00:02 +0000

AstraZeneca PLC could come out the big winner if Sun Pharmaceutical Industries Ltd. ’s proposed takeover of Ranbaxy Laboratories Ltd. impacts the launch timeline for generic versions of the b

Second-To-Market Strategy In HCV: An Interview With AbbVie’s Barry Bernstein

Mon, 03 Mar 2014 05:00:48 +0000

Having completed a rigorous six-trial Phase III program for its trio of direct-acting antiviral (DAA) candidates for hepatitis C infection, AbbVie Inc. now is on the verge of filing its combinatio

Asia On The Move: Personnel News From AstraZeneca, Novartis, Teva

Brian Yang — Fri, 12 Apr 2013 18:25:01 +0000

Asia On The Move highlights personnel changes in the Asia Pacific region. The previous issue covered the reorganization and personnel moves inside China FDA ( [A#28130325015] ). Teva Hires Lilly Vete

Deals Of The Week: Big Pharmas Hoard Cash, But Aren’t Buying Yet In 2013

Paul Bonanos|Jessica Merrill|Sten Stovall — Mon, 25 Mar 2013 04:00:50 +0000

For pharmas making all but the largest acquisitions, cash is king. From speculative buyouts of preclinical start-ups all the way through bolt-on deals worth a few billion dollars, pharmas typically sp

Japan's Biennial Price Cuts Spare Innovation But Punish Overachievers

Daniel Poppy — Tue, 06 Mar 2012 05:00:00 +0000

TOKYO – Victims of their own success, 16 drugs in Japan, including Eisai Co. Ltd. 's blockbuster Alzheimer’s therapy Aricept (donepezil), have received steep price cuts during the country’s bienn

Deals Of The Week: Shire/Janssen, Pfizer/SFJ Pharma, AstraZeneca/IMS Health

Melanie Senior|Wendy Diller|John Davis|Paul Bonanos — Mon, 16 Jan 2012 05:00:00 +0000

Shire/Janssen Resolor has produced minimal sales to date, but Shire PLC increased its bet on the chronic constipation drug Jan. 10, acquiring U.S. rights to the compound from Janssen Pharmaceu